Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.36 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | BAX | Q07812 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208440 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| SCHEMBL6921848 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| Bromide SCHEMBL29093982 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| Ammonia Solution, Strong SCHEMBL1308109 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| Hydrochloric Acid SCHEMBL7515490 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2CHRM5CHRM3POLBCXCR4 | |
| Hydrochloric Acid SCHEMBL6619286 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2CHRM5CHRM3POLBCXCR4 | |
| SCHEMBL11682700 | 0.77 | CHRM5 (0.43) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| SCHEMBL1374432 | 0.77 | — | — | |
| SCHEMBL1393824 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 | |
| SCHEMBL13833229 | 0.76 | SMN1; SMN2 (0.47) | SMN1; SMN2CHRM5CHRM3PADI1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592083-A1 | FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2013-05-15 | — | — | EP | claimed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | claimed |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2011-11-24 | — | — | US | claimed |
| EP-1784399-B1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-15 | — | — | EP | claimed |
| JP-4674236-B2 | — | — | 2011-04-20 | — | — | JP | claimed |
| US-7910585-B2 | Pyrimidine derivatives | NOVARTIS AG (CH) | 2011-03-22 | — | — | US | claimed |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2009-10-01 | — | — | US | claimed |
| US-20080293708-A1 | Pyrimidine Derivatives | NOVARTIS AG (CH) | 2008-11-27 | — | — | US | claimed |
| JP-2008510765-A | — | — | 2008-04-10 | — | — | JP | claimed |
| EP-1807429-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM, LLC (BM) | 2007-07-18 | — | — | EP | claimed |
| EP-1784399-A2 | PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2007-05-16 | — | — | EP | claimed |
| WO-2006047516-A2 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2006-05-04 | — | — | WO | claimed |
| WO-2006021457-A2 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2006-03-02 | — | — | WO | claimed |
| EP-2592083-A1 | FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2013-05-15 | — | — | EP | disclosed |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | IRM LLC (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8158634-B2 | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | IRM LLC (BM) | 2012-04-17 | — | — | US | disclosed |
| US-5658914-A | ANTIESTROGENS, ANTITUMOR AGENTS | RESEARCH CORPORATION TECHNOLOGIES (US) | 1997-08-19 | — | — | US | disclosed |
| US-5422367-A | A hormon inhibitors and for inhibiting the development of an estrogen-dependent tumor | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-06-06 | — | — | US | disclosed |
| US-5324736-A | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5098903-A | Halocyclopropanes | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 1992-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | AURKA, AURKC, AURKB | SMN1; SMN2 4624/4885CHRM5 4406/4885CHRM3 4030/4885 |
| US-20080293708-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | SMN1; SMN2 1651/4885CHRM5 4642/4885CHRM3 4717/4885 |
| US-20120225869-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | SMN1; SMN2 3746/4885CHRM5 952/4885CHRM3 770/4885 |
| US-20090247517-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY | CNR1, CNR2, FAAH | SMN1; SMN2 3746/4885CHRM5 952/4885CHRM3 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.